UBS Group
VAXX

UBS Group’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

UBS Group’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-42,787
Closed -$30.7K – 10396
2024
Q1 		$30.7K Sell
42,787
-233
-0.5% -$169 ﹤0.01% 6731
2023
Q4 		$36.6K Buy
43,020
+33,656
+359% +$32.5K ﹤0.01% 6725
2023
Q3 		$12.8K Sell
9,364
-15,607
-63% -$33.8K ﹤0.01% 7010
2023
Q2 		$62.9K Buy
24,971
+22,304
+836% +$47.2K ﹤0.01% 6346
2023
Q1 		$6.05K Buy
2,667
+1,392
+109% +$3.53K ﹤0.01% 7965
2022
Q4 		$1.78K Sell
1,275
-4,581
-78% -$7.7K ﹤0.01% 9792
2022
Q3 		$12K Buy
+5,856
New +$12.2K ﹤0.01% 8211
2022
Q1 		– Sell
-2,566
Closed -$14K – 11135
2021
Q4 		$14K Buy
+2,566
New +$26.5K ﹤0.01% 8373

Other funds holding VAXX

SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

UBS Group's VAXX Position: Q2 2024 in Review

UBS Group sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 42,787 shares — an estimated $30.7K sold.

UBS Group first reported a position in VAXX in Q4 2021 and held it in 8 quarters. The position peaked at $62.9K in Q2 2023. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

  • UBS Group reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 42,787 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $30.7K.
  • UBS Group first reported a position in Vaxxinity, Inc. Class A Common Stock in Q4 2021 and held it in 8 quarters.
  • UBS Group's Vaxxinity, Inc. Class A Common Stock position peaked at $62.9K in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.